Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Minnesota Equal Rights Amendment fails in acrimonious end to legislative session
Deadly crash in Bell being investigated as a homicide
Prisoner and corrections officers take refuge in van after shots fired
Australian experts play down fears of a new epidemic out of China
Government warned against repealing Oranga Tamariki's Treaty commitments
Brazil's 2024 budget predicts 2.26% economic growth
Kristin Cavallari, 37, ignores critics of her age
Quad summit: Ditch trade bans and we'll talk, Albanese tells China
Israeli army says it kills over 130 militants in E. Rafah
HK must remain vigilant against 'soft resistance'